Altimmune to Present at Upcoming Investor and Scientific Conferences
Altimmune, Inc. (Nasdaq: ALT) announced its management team's participation in several upcoming virtual conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced its management team's participation in several upcoming virtual conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will take place from November 29 to December 2, 2021. The 5th Annual NASH Summit 2021 is scheduled for November 30, 2021, at 9:00 am Eastern Time. Lastly, Altimmune will present at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, at 10:55 am Eastern Time. Presentation materials and webcasts are accessible on their website.
Details
News Market Reaction – ALT
The recorded move for ALT in the trading session of this news was +2.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences:
- Piper Sandler 33rd Annual Virtual Healthcare Conference
November 29-December 2, 2021
Webcast available now
- 5th Annual NASH Summit 2021
November 30, 2021
9:00 am Eastern Time
- 4th Annual Evercore ISI HealthCONx Conference
December 2, 2021
10:55 am Eastern Time
Presentation materials, including webcast links to the Piper Sandler and Evercore ISI presentations, will be accessible on the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.